Global Hepatitis Summit 2026

Topics

• Public health interventions in liver diseases
  • Global achievements and failures in viral hepatitis elimination
  • Public health tools to eliminate viral hepatitis
  • Public health interventions to eliminate NAFLD/NASH
  • HCV elimination in Egypt: a success story
• Innovations in liver disease therapy: present and future
  • Innovations in antiviral immunotherapy
  • Innovations in direct-acting antiviral therapies
  • Innovations in hepatocellular carcinoma therapy
  • Innovations in liver fibrosis and NASH therapy
• Global Hepatitis Summit Debrief
  • HBV/HDV Debrief
  • HCV Debrief
  • HCC Debrief
  • NAFLD/NASH Debrief
• New vaccine approaches for liver diseases
  • Towards an HCV vaccine
  • The story and future of RNA vaccines
  • Implementing global vaccination strategies
  • The future of therapeutic vaccines for viral infections
• HCV immunology
  • Adaptive immune responses against HCV
  • Innate immune responses against HCV
• HCV/flavivirus virology
  • HCV entry: lessons learnt for other viruses
  • What did HCV teach us on flavivirus virology
• HBV/HDV immunology
  • Liver compartmentalization of anti-HBV immune responses
  • Immunological phenotyping of HBV infections
• HBV/HDV virology
  • Update on HDV virology
  • Update on HBV virology
• NASH targets for new therapies
  • Preclinical assessment of NASH compounds
  • Molecular targets for NASH therapy
• HBV/HDV treatment targets
  • Targeting HBV RNAs for therapy
  • Targeting HBV capsids for therapy
• HEV virology and persistence
  • Mechanisms of HEV persistance in immunodepressed patients
  • Update on HEV virology
• HCC targets for new therapies
  • Immunological targets for HCC therapy
  • Molecular targets for HCC therapy
• Liver inflammation and fibrogenesis
  • Mechanisms of liver fibrogenesis
  • Mechanisms of NAFLD/NASH-associated liver inflammation